MeSH tree: C04.557.470.200.025
A research team led by Prof. Wang Hongzhi at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has found a novel role of prostaglandin E synthase 3 (PTGES3) in liver cancer, revealing how it drives both ...
4 hours ago
0
0
A new Houston Methodist study highlights a promising noninvasive imaging technique that could help doctors more accurately diagnose papillary thyroid cancer, the most common type of thyroid cancer.
Jun 25, 2026
0
3
The research group led by CIC biomaGUNE's Ikerbasque Research Professor Aitziber L. Cortajarena has developed an innovative anti-fibrotic and anti-tumor treatment by binding a synthetic protein to gold nanoclusters (small ...
Jun 23, 2026
0
5
A risk model that combines a mammographic artificial intelligence (AI) risk score with polygenic and clinical risk scores more accurately identifies women at high risk of developing breast cancer than clinical risk scores ...
Jun 23, 2026
0
14
A team of scientists from the Barbara Ann Karmanos Cancer Institute, Wayne State University and institutions across the U.S. have published a new paper on the role of TGFBR1*6A, a naturally occurring genetic mutation in the ...
Jun 23, 2026
0
4
A liver cancer diagnosis frequently leads to surgery, with the goal of completely removing all malignant tissue. To ensure that no tumor remains in the organ, the resected tissue is subjected to frozen-section analysis during ...
Jun 22, 2026
0
3
The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma ...
Jun 19, 2026
0
7
Liver cancer is one of the fastest-rising causes of cancer-related deaths in the UK and the third-leading cause of cancer deaths worldwide.
Jun 17, 2026
0
2
Belzutifan, a first-in-class drug that arose from scientific discoveries at UT Southwestern Medical Center, has been approved by the Food and Drug Administration to treat some patients with earlier-stage kidney cancers in ...
Jun 16, 2026
0
4
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component ...
Jun 15, 2026
0
3
